Navana Pharmaceuticals Ltd. is seeking a 26.61 million euro long-term foreign loan from Germany to expand its production capacity, following strong earnings and operating cash flow in the first nine months of the current financial year.
The listed drug manufacturer said its board approved proceeding with a 12-year loan facility from Germany-based AKA Ausfuhrkredit-Gesellschaft mbH, arranged through KGMC Financial Service, Bangladesh. The financing remains subject to regulatory approvals and completion of due diligence.
The announcement comes alongside improved financial results for the July 2025–March 2026 period. Navana Pharma reported earnings per share (EPS) of Tk4.59, up 31.52 per cent from Tk3.49 in the same period last year. For the January–March quarter alone, EPS rose to Tk1.22 from Tk1.01.
The company attributed earnings growth to higher sales revenue and tighter cost management. Net operating cash flow per share also improved to Tk15.44 from Tk10.22, reflecting stronger cash collection from customers.
Net asset value per share increased to Tk49.53 on 31 March 2026, compared with Tk45.29 at the end of June 2025, highlighting a stronger balance sheet ahead of planned capacity expansion.
Navana Pharma shares closed 1.8 per cent higher at Tk75.4 on the Dhaka Stock Exchange on Thursday.
